Vendor Intelligence Report: Oupeptide

Published 3 Jul 2026. 27-page investigative report on who is behind Oupeptide: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Oupeptide is a mixed, product-specific vendor, not a single quality signal. Across 179 Finnrick lab tests, the record is 128 pass / 51 fail, an overall pass rate of 72%. The spread matters: GHK-Cu is the cleanest in-catalog positive, tirzepatide and retatrutide are the better-supported moderate choices, and tesamorelin is the clearest avoid signal. The full report shows where those results tighten or deteriorate under stricter grading.

The corporate trail is more troubling than the headline lab rate. Oupeptide presents a US/NY location string, but the ZIP formatting does not reconcile with New York and searched US registries did not return an Oupeptide entity. The strongest public corporate anchor is a 1688 profile for Guangzhou Oupeptide Biomedicine Co., Ltd., a body-care/collagen-facing business; the domain itself is privacy-protected and first archived with a Simplified Chinese WordPress interface before English localization.

The operational model also looks fragmented. The investigation ties the main site to a cloned-domain network through shared branding, Hostinger ranges, common WooCommerce/Omnisend/GoAffPro tooling, and overlapping WhatsApp agents, including a shared Mia number on PFPeptide. Shipping language describes special-line logistics with tracking only after customs clearance, while Janoshik COAs show third-party sample testing but do not prove factory identity or batch-to-buyer continuity.

Inside the full report:

  • Appendix A per-product pass/fail rates and methodology-divergence charts for all ten tested products
  • 1688 corporate profile analysis for Guangzhou Oupeptide Biomedicine Co., Ltd.
  • US registry search negatives and the US/NY ZIP reconciliation trail
  • Six-domain sister-site map with shared agent, hosting, and tooling anchors
  • Shipping, payment, COA, and community-warning evidence with confidence levels

Risk assessment

  • Product-quality risk for fail-heavy peptides — high: Tesamorelin (36.37%; 4 pass / 10 fail), TB-500 (33.24%; 1 pass / 3 fail), and BPC-157 (49.89%; 4 pass / 4 fail) are poor choices; GHK-Cu/Tirzepatide/Retatrutide test materially better.
  • Misrepresented identity and manufacturing-capability risk — high: The site presents US/NY and own-lab/production-line claims, but searched US registries found no Oupeptide entity and records point to a Guangzhou body-care/collagen corporate anchor.
  • Supply-chain and customs-opacity risk — high: Shipping page describes special-line logistics with tracking only after customs; no public ImportGenius record surfaced and 1688 foreign-trade field says not supported.
  • Brand-confusion and off-channel-purchase risk — high: At least six cloned/related domains and 14 WhatsApp agents share infrastructure or contact anchors, with no reviewed authorized-domain/reseller list or anti-counterfeit program.
  • COA-chain-of-custody risk — medium: Janoshik COAs are better than vendor-only screenshots but list oupeptide.com as Client and Manufacturer and do not prove factory identity or batch-to-buyer continuity.
  • Customer-dispute and scam-report risk — medium: Community scam warnings, a removed promotional Reddit post, a deleted GLP-1 Forum allegation, and ScamAdviser’s low score create a caution signal, though several sources are third-party or removed.